Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer
10.1097/JTO.0b013e318168c801
Saved in:
Main Authors: | Wong, A.S., Soong, R., Seah, S.B.-K., Lim, S.-W., Chuah, K.-L., Nga, M.-E., Chin, T.-M., Soo, R.A. |
---|---|
Other Authors: | PHARMACY |
Format: | Article |
Published: |
2014
|
Subjects: | |
Online Access: | http://scholarbank.nus.edu.sg/handle/10635/109333 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
EGFR Mutant Structural Database: Computationally predicted 3D structures and the corresponding binding free energies with gefitinib and erlotinib
by: Ma, L, et al.
Published: (2020) -
Lung cancer response to gefitinib, then erlotinib, then gefitinib again
by: Wong, A.S., et al.
Published: (2014) -
Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: Meta-analysis of phase III trials
by: Ku, G.Y., et al.
Published: (2016) -
Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations
by: Yeo, W.-L., et al.
Published: (2011) -
EGFR S1166 phosphorylation induced by a combination of EGF and gefitinib has a potentially negative impact on lung cancer cell growth
by: Assiddiq, B.F., et al.
Published: (2014)